BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32696549)

  • 1. Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes.
    Pribyl M; Hubackova S; Moudra A; Vancurova M; Polackova H; Stopka T; Jonasova A; Bokorova R; Fuchs O; Stritesky J; Salovska B; Bartek J; Hodny Z
    Mol Oncol; 2020 Oct; 14(10):2403-2419. PubMed ID: 32696549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suprabasin-A Review.
    Pribyl M; Hodny Z; Kubikova I
    Genes (Basel); 2021 Jan; 12(1):. PubMed ID: 33477529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-regulated suprabasin is essential for stress-induced stem-like cell conversion and therapy resistance of human malignancies.
    Hubackova S; Pribyl M; Kyjacova L; Moudra A; Dzijak R; Salovska B; Strnad H; Tambor V; Imrichova T; Svec J; Vodicka P; Vaclavikova R; Rob L; Bartek J; Hodny Z
    Mol Oncol; 2019 Jul; 13(7):1467-1489. PubMed ID: 30919591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suprabasin: Role in human cancers and other diseases.
    Tan H; Wang L; Liu Z
    Mol Biol Rep; 2022 Feb; 49(2):1453-1461. PubMed ID: 34775572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of suprabasin induces aberrant differentiation and apoptosis of epidermal keratinocytes: Possible role for atopic dermatitis.
    Aoshima M; Phadungsaksawasdi P; Nakazawa S; Iwasaki M; Sakabe JI; Umayahara T; Yatagai T; Ikeya S; Shimauchi T; Tokura Y
    J Dermatol Sci; 2019 Sep; 95(3):107-112. PubMed ID: 31399284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology.
    Stergiou IE; Kambas K; Poulaki A; Giannouli S; Katsila T; Dimitrakopoulou A; Vidali V; Mouchtouris V; Kloukina I; Xingi E; Pagakis SN; Probert L; Patrinos GP; Ritis K; Tzioufas AG; Voulgarelis M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.
    Vaxevanis CK; Bauer M; Subbarayan K; Friedrich M; Massa C; Biehl K; Al-Ali HK; Wickenhauser C; Seliger B
    Oncoimmunology; 2023; 12(1):2152998. PubMed ID: 36531688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suprabasin as a novel tumor endothelial cell marker.
    Alam MT; Nagao-Kitamoto H; Ohga N; Akiyama K; Maishi N; Kawamoto T; Shinohara N; Taketomi A; Shindoh M; Hida Y; Hida K
    Cancer Sci; 2014 Dec; 105(12):1533-40. PubMed ID: 25283635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome.
    Yang WC; Lin SF; Wang SC; Tsai WC; Wu CC; Wu SC
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
    Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
    Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
    Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
    Tong H; Hu C; Zhuang Z; Wang L; Jin J
    Leuk Lymphoma; 2012 Dec; 53(12):2412-8. PubMed ID: 22632108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine.
    Moudra A; Hubackova S; Machalova V; Vancurova M; Bartek J; Reinis M; Hodny Z; Jonasova A
    Oncoimmunology; 2016; 5(10):e1183860. PubMed ID: 27853634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome.
    Schlesinger M; Silverman LR; Jiang JD; Yagi MJ; Holland JF; Bekesi JG
    J Clin Lab Immunol; 1996; 48(4):149-66. PubMed ID: 9819667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suprabasin-derived polypeptides: SBSN(50-63) induces inflammatory response via TLR4-mediated mast cell activation.
    Zhou T; Du X; Zhang L; Zheng Y; Jia T; Song X; Che D; Geng S
    Inflammopharmacology; 2023 Jun; 31(3):1329-1339. PubMed ID: 36745245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
    Diamantopoulos PT; Kontandreopoulou CN; Symeonidis A; Kotsianidis I; Pappa V; Galanopoulos A; Vassilakopoulos T; Dimou M; Solomou E; Kyrtsonis MC; Siakantaris M; Angelopoulou M; Kourakli A; Papageorgiou S; Christopoulou G; Roumelioti M; Panayiotidis P; Viniou NA;
    Ann Hematol; 2019 Jun; 98(6):1383-1392. PubMed ID: 30877373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes.
    Zhang Z; Li X; Guo J; Xu F; He Q; Zhao Y; Yang Y; Gu S; Zhang Y; Wu L; Chang C
    Eur J Haematol; 2013 May; 90(5):375-84. PubMed ID: 23331180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes.
    Picou F; Vignon C; Debeissat C; Lachot S; Kosmider O; Gallay N; Foucault A; Estienne MH; Ravalet N; Bene MC; Domenech J; Gyan E; Fontenay M; Herault O
    Blood Adv; 2019 Dec; 3(24):4271-4279. PubMed ID: 31869414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.